Trust Signals
Key Takeaways
- Semaglutide 2.4 mg weekly produced approximately 14.9 percent mean body weight reduction in the STEP 1 RCT (n=1961); this is the strongest human evidence for any weight-loss peptide.
- Tirzepatide 15 mg weekly produced approximately 20.9 percent mean body weight reduction in SURMOUNT-1 (n=2539), currently the largest effect size seen in a weight-loss peptide RCT.
- AOD-9604 failed to beat placebo in a phase 2b human trial despite promising rodent data; it is not approved for weight loss anywhere today.
- CJC-1295, Ipamorelin, and GHRP-2 have no human RCT evidence for body fat reduction; their fat-loss rationale is entirely mechanistic extrapolation from GH physiology.
- Grey-market peptide vials frequently contain less than labeled peptide content or detectable endotoxin; a COA with HPLC above 98 percent and LAL endotoxin testing is the minimum credibility bar.
What Are the Best Peptides for Weight Loss?
Table of Contents
- Evidence Ledger: All Major Candidates Graded
- The Tier 1 Peptides: GLP-1 and GIP Agonists
- Mechanism with Numbers: How GLP-1 Agonists Drive Fat Loss
- The Research-Grade Peptides: CJC-1295, Ipamorelin, AOD-9604, GHRP-2
- What Most Pages Get Wrong About AOD-9604
- Honest Head-to-Head: Peptides vs. Other Approved Weight-Loss Options
- The Chemistry Behind the Rules: Why These Peptides Degrade Fast
- Operational and Label Literacy: Reading a COA, Dosing Tables, Reconstitution
- Can You Stack Peptides for Better Results?
- FAQ
- Sources
Evidence Ledger: All Major Candidates Graded
| Peptide | Best Evidence Type | Effect on Body Weight | Confidence | Approved for Weight Loss? |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Large human RCT (STEP 1, n=1961) | Approx. 14.9% reduction vs. 2.4% placebo | High | Yes (FDA, 2021) |
| Tirzepatide (Zepbound) | Large human RCT (SURMOUNT-1, n=2539) | Approx. 20.9% reduction at 15 mg | High | Yes (FDA, 2023) |
| Liraglutide (Saxenda) | Human RCT (SCALE trial) | Approx. 8% reduction vs. 2.6% placebo | High | Yes (FDA, 2014) |
| AOD-9604 | Phase 2b human trial (failed primary endpoint) | Not significantly different from placebo in humans | Very Low | No |
| CJC-1295 / Ipamorelin | Mechanistic extrapolation; no weight-loss RCT | No direct evidence of body fat reduction | Very Low | No |
| GHRP-2 / GHRP-6 | Small human PK studies, animal models | GH pulse increases lipolysis in theory only | Very Low | No |
| BPC-157 | Animal studies only | No weight-loss signal in any human data | Very Low | No |
What Are the Tier 1 Peptides: GLP-1 and GIP Agonists?
Semaglutide, tirzepatide, and liraglutide are the only peptides with replicated, large-scale human RCT evidence for weight loss. They are structurally modified peptides designed to mimic endogenous incretin hormones.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Semaglutide (Wegovy): A 31-amino-acid GLP-1 analogue with a C18 fatty diacid chain linked via a linker to lysine at position 26. The fatty acid chain enables albumin binding, extending plasma half-life to approximately 7 days, enabling once-weekly subcutaneous dosing. FDA-approved at 2.4 mg weekly for chronic weight management.
Tirzepatide (Zepbound): A 39-amino-acid dual GIP/GLP-1 receptor agonist. It binds GIP receptors with potency comparable to native GIP and GLP-1 receptors with lower intrinsic potency than semaglutide, but the dual mechanism appears to produce additive or synergistic metabolic effects. FDA-approved in 2023 at doses up to 15 mg weekly for obesity.
Liraglutide (Saxenda): An earlier GLP-1 analogue requiring daily injection and achieving roughly half the weight reduction of semaglutide. Still prescribed but largely superseded for weight loss by weekly agents.
What Is the Mechanism with Numbers: How Do GLP-1 Agonists Drive Fat Loss?
GLP-1 receptors are expressed in the hypothalamus (arcuate and paraventricular nuclei), brainstem (nucleus tractus solitarius), and peripheral tissues including the stomach and pancreatic beta cells. Agonism at central GLP-1 receptors reduces appetite by increasing satiety signaling through POMC/CART neurons and suppressing NPY/AgRP pathways.
In the STEP 1 trial (Wilding et al., NEJM 2021), participants receiving semaglutide 2.4 mg weekly for 68 weeks lost a mean of 14.9 percent of body weight compared with 2.4 percent in the placebo group. That is a net treatment effect of approximately 12.4 percentage points in a population with mean baseline BMI of 37.9.
In SURMOUNT-1 (Jastreboff et al., NEJM 2022), tirzepatide 15 mg produced a mean weight reduction of approximately 20.9 percent over 72 weeks versus approximately 3.1 percent for placebo, a net treatment effect of roughly 17.8 percentage points.
What the mechanism does NOT prove: These central appetite effects do not mean the drugs work equally in everyone. Approximately 15 to 20 percent of STEP 1 participants were classified as low responders (less than 5 percent weight loss). GLP-1 receptor gene variants (notably GLP1R rs6923761) have been studied as potential moderators, but clinical genotyping is not standard practice.
What Do the Research-Grade Peptides Actually Do?
AOD-9604: A synthetic 16-amino-acid fragment corresponding to the C-terminal region of human growth hormone (residues 177 to 191). In rodent models, it stimulated lipolysis and inhibited lipogenesis without raising IGF-1. The Australian TGA briefly approved it as a prescription obesity drug, but approval was withdrawn. A phase 2b human study enrolled over 500 participants and did not meet its primary weight-loss endpoint.
CJC-1295: A 30-amino-acid GHRH analogue with a drug affinity complex (DAC) modification that covalently binds albumin, extending half-life to days rather than minutes. It raises mean 24-hour GH levels and IGF-1, but no human trial has measured body fat composition change as a primary endpoint.
Ipamorelin: A pentapeptide ghrelin receptor agonist (GHSR-1a) that stimulates pulsatile GH release selectively, with less effect on cortisol and prolactin than GHRP-2. The fat-loss rationale is that GH promotes lipolysis in adipocytes via hormone-sensitive lipase activation. This is mechanistically plausible, but no human RCT confirms that Ipamorelin-driven GH pulses translate into net body fat reduction.
GHRP-2 and GHRP-6: Older hexapeptide GH secretagogues. GHRP-6 notably stimulates appetite via ghrelin pathways, which is the opposite of a weight-loss property.
What Most Pages Get Wrong About AOD-9604
Nearly every medspa and peptide vendor page describes AOD-9604 as "clinically proven for fat loss" and cites rodent studies or the brief Australian TGA approval without disclosing that the drug failed its pivotal human trial. This is the single most important omission in the AOD-9604 literature online.
The full story: Metabolic Pharmaceuticals (an Australian company) conducted a phase 2b trial in overweight adults. The trial failed to show statistically significant weight reduction versus placebo. Metabolic Pharmaceuticals subsequently abandoned the obesity program. The TGA approval was withdrawn. AOD-9604 has not been approved by the FDA at any point for any indication.
Rodent lipolysis results are real and replicated. But adipocyte biology in rodents differs meaningfully from humans in receptor density, adipose distribution, and hormonal feedback. Extrapolating rodent lipolysis data to human weight loss has failed repeatedly across metabolic pharmacology, and AOD-9604 is a clear example.
How Do These Peptides Compare to Other Weight-Loss Options?
| Option | Mean Weight Loss (Human RCT) | Evidence Quality | Regulatory Status | Where Peptides Lose |
|---|---|---|---|---|
| Tirzepatide (peptide) | Approx. 20.9% (SURMOUNT-1) | High | FDA-approved | Cost, GI side effects, injection requirement |
| Semaglutide (peptide) | Approx. 14.9% (STEP 1) | High | FDA-approved | Cost, nausea rates approx. 44% in STEP 1 |
| Phentermine/topiramate (small molecule) | Approx. 10% (EQUIP/CONQUER trials) | High | FDA-approved (Qsymia) | CNS side effects, teratogenicity, no CV outcome data |
| Orlistat (small molecule) | Approx. 3 to 5% above placebo | High | FDA-approved | GI intolerance, poor adherence, modest effect |
| CJC-1295/Ipamorelin (research peptides) | No RCT data | Very Low | Not approved | Loses on every clinical evidence dimension |
| AOD-9604 (research peptide) | Failed phase 2b | Very Low | Not approved | Loses on efficacy and regulatory status |
| Intensive lifestyle intervention | Approx. 5 to 7% sustained at 1 year | High | N/A | Requires sustained effort, less effective than GLP-1 agonists |
What Is the Chemistry Behind the Rules: Why Do These Peptides Degrade?
Peptides are chains of amino acids linked by amide bonds. Those bonds are vulnerable to two main degradation pathways that determine how you store and handle these compounds.
Hydrolysis: In aqueous solution, water molecules attack the amide carbonyl carbon, cleaving the peptide bond. The rate increases with temperature and, depending on the peptide sequence, with extremes of pH. This is why reconstituted peptide solutions must be refrigerated (ideally at 2 to 8 degrees Celsius) and used within a manufacturer-specified window (often 28 to 30 days for GLP-1 pens; shorter for reconstituted research vials). Lyophilized (freeze-dried) powder is far more stable because there is no aqueous phase to drive hydrolysis.
Oxidation: Methionine and cysteine residues are the most vulnerable. Methionine sulfoxide formation reduces binding affinity to target receptors. Exposure to light (particularly UV) and dissolved oxygen accelerates this. Bacteriostatic water (which contains 0.9% benzyl alcohol) is preferred over sterile water for research-use reconstitution precisely because it slows microbial contamination and provides a mild antioxidant environment, not because benzyl alcohol chemically protects the peptide bond itself.
Why this matters for sourcing: A peptide vial that shipped unrefrigerated for several days in summer heat has likely degraded. You cannot detect partial hydrolysis by appearance. The solution may look perfectly clear while having lost a substantial fraction of its bioactive peptide content. This is why storage temperature during transit matters as much as storage at your end.
Why you should not mix with vitamin C or acidic buffers: Acidic conditions below roughly pH 4 accelerate hydrolysis of many peptide bonds, particularly at aspartate residues. Vitamin C (ascorbic acid) drops solution pH and is also a reducing agent that can interfere with disulfide-containing peptides. The rule is not a myth; the underlying chemistry is real.
How Do You Read a COA and Dose These Compounds Correctly?
COA minimum requirements:
- HPLC purity: Should state the method (reverse-phase HPLC) and the purity percentage. Anything below 98 percent raises quality concerns for research use.
- Mass spectrometry: Confirms the molecular weight matches the target peptide. A correct mass rules out substitution with a cheaper peptide.
- Endotoxin testing: Should be performed via LAL (limulus amebocyte lysate) assay with a stated result in EU/mg or EU/mL. Absence of this test on a COA is a significant red flag for any injectable compound.
- Batch number: Must appear on both the COA and the vial label. A COA without a traceable batch number is unverifiable and should be rejected.
Reconstitution math (general research context only): A 5 mg lyophilized vial reconstituted with 2 mL bacteriostatic water gives a concentration of 2,500 mcg per mL (2.5 mg/mL). A 100 mcg dose would require 0.04 mL (4 units on a U-100 insulin syringe). Always verify the final concentration before drawing a dose. Label the vial with date of reconstitution and discard after the recommended window.
GLP-1 agonist approved dosing (prescriber reference, not a dosing recommendation):
| Drug | Starting Dose | Target/Max Dose | Route | Escalation Period |
|---|---|---|---|---|
| Semaglutide (Wegovy) | 0.25 mg weekly | 2.4 mg weekly | Subcutaneous | 16 to 20 weeks per FDA label |
| Tirzepatide (Zepbound) | 2.5 mg weekly | 15 mg weekly | Subcutaneous | 20 weeks per FDA label |
| Liraglutide (Saxenda) | 0.6 mg daily | 3.0 mg daily | Subcutaneous | 5 weeks per FDA label |
Degraded product signs: Visible particulate matter, yellow or brown discoloration, or failure to clarify after reconstitution are reasons to discard immediately. A cloudy GLP-1 pen cartridge should not be used. These visual signs indicate aggregation or contamination but the absence of visual changes does not guarantee potency.
Can You Stack Peptides for Better Weight Loss Results?
Stacking CJC-1295 with Ipamorelin is the most commonly discussed combination in research peptide communities. The rationale is that CJC-1295 raises baseline GH via GHRH receptor activation while Ipamorelin adds pulsatile GH release via GHSR-1a, producing a synergistic GH profile. This reasoning is mechanistically coherent.
What is missing: no human RCT has tested CJC-1295 plus Ipamorelin as a weight-loss intervention with body composition as a primary endpoint. The synergistic GH profile is documented in pharmacokinetic studies, but translating a GH pulse profile into meaningful fat mass reduction in humans has not been demonstrated in this combination. The claim that stacking beats monotherapy on fat loss is speculation.
Stacking research peptides with approved GLP-1 agonists raises uncharacterized interaction risks and is not a practice with any controlled evidence base.
FAQ
What are the best peptides for weight loss?
By clinical evidence, semaglutide and tirzepatide (GLP-1/GIP receptor agonists) are the strongest weight-loss peptides, producing 15 to 22 percent body weight reduction in large RCTs. Research-only peptides like AOD-9604 and CJC-1295/Ipamorelin have far weaker evidence and no approved weight-loss indication.
Is semaglutide a peptide?
Yes. Semaglutide is a 31-amino-acid GLP-1 receptor agonist peptide, modified with a C18 fatty acid chain that extends its half-life to roughly 7 days, allowing once-weekly dosing. It is FDA-approved for weight management under the brand name Wegovy at 2.4 mg weekly.
Does AOD-9604 actually work for weight loss in humans?
Evidence is weak. AOD-9604 showed fat-reducing effects in rodent studies and received Australian TGA approval for obesity, but a phase 2b human trial (conducted by Metabolic Pharmaceuticals) failed to show statistically significant weight loss versus placebo. It is not approved for weight loss anywhere today.
What is CJC-1295 and does it cause fat loss?
CJC-1295 is a GHRH analogue that raises growth hormone and IGF-1 levels. Elevated GH can increase lipolysis, but no human RCT has demonstrated meaningful body fat reduction from CJC-1295 alone. Any fat-loss claims rely on extrapolating GH physiology, not direct trial evidence.
How does tirzepatide compare to semaglutide for weight loss?
In the SURMOUNT-1 trial, tirzepatide 15 mg produced a mean body weight reduction of approximately 20.9 percent over 72 weeks. The STEP 1 trial showed semaglutide 2.4 mg reduced weight by approximately 14.9 percent. Tirzepatide's dual GLP-1/GIP mechanism appears to outperform semaglutide on average weight reduction.
What peptides are used in compounded weight loss injections?
Compounded products have included semaglutide, tirzepatide, CJC-1295, Ipamorelin, and AOD-9604. Semaglutide and tirzepatide compounding was permitted during shortage periods under FDA enforcement discretion. The FDA has signaled compounded semaglutide products face increasing scrutiny as shortage designations change.
What is Ipamorelin and how does it relate to fat loss?
Ipamorelin is a selective ghrelin receptor agonist (GHSR-1a) that stimulates GH secretion with minimal cortisol or prolactin effect compared to older secretagogues. Its connection to fat loss is indirect, via GH-driven lipolysis. No human RCT demonstrates direct body fat reduction from Ipamorelin.
Are peptides for weight loss safe?
Safety depends entirely on which peptide. FDA-approved GLP-1 agonists have well-characterized safety profiles from large trials, with the main concerns being GI side effects and rare thyroid C-cell tumor risk in animal models. Research peptides like AOD-9604 and CJC-1295 have limited human safety data and unregulated purity in grey-market sources.
Can you stack peptides for better weight loss results?
Stacking is common in research communities (e.g., CJC-1295 plus Ipamorelin) but has no controlled human trial evidence for weight loss superiority over monotherapy. Stacking GLP-1 agonists with unregulated peptides carries unknown interaction risks and is not medically endorsed.
How do I read a peptide COA to check purity?
A credible COA should include HPLC purity (target above 98 percent for research use), mass spectrometry confirmation of molecular weight, endotoxin testing (LAL assay), and a batch number traceable to a third-party lab. Reject any COA that shows only a single purity number without the analytical method stated.
What happens when a peptide vial degrades?
Degraded peptides typically show visible particulate matter, discoloration (yellow or brown), or a solution that no longer clears after reconstitution. Chemically, oxidation of methionine or cysteine residues and hydrolysis of peptide bonds reduce potency and can generate immunogenic fragments. Never inject a cloudy or discolored solution.
Are weight loss peptides banned in sport?
WADA prohibits peptide hormones, growth factors, and related substances under its annual Prohibited List. GH secretagogues including Ipamorelin and CJC-1295 fall under this category. GLP-1 agonists are not currently on the WADA Prohibited List, but athletes should verify the current list annually.
Sources
- Wilding JPH, Batterham RL, Calanna S, et al. "Once-Weekly Semaglutide in Adults with Overweight or Obesity." New England Journal of Medicine. 2021;384(11):989-1002. (STEP 1 trial)
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. "Tirzepatide Once Weekly for the Treatment of Obesity." New England Journal of Medicine. 2022;387(3):205-216. (SURMOUNT-1 trial)
- Pi-Sunyer X, Astrup A, Fujioka K, et al. "A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management." New England Journal of Medicine. 2015;373(1):11-22. (SCALE Obesity and Prediabetes trial)
- FDA. "Wegovy (semaglutide) Prescribing Information." U.S. Food and Drug Administration. 2021. Accessed 2026.
- FDA. "Zepbound (tirzepatide) Prescribing Information." U.S. Food and Drug Administration. 2023. Accessed 2026.
- Heffernan MA, Thorburn AW, Fam B, et al. "Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone fragment 177-191." International Journal of Obesity. 2001;25(10):1442-1449. (AOD-9604 rodent data)
- Alba M, Fintini D, Sagazio A, et al. "Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analogue, normalizes growth in the GHRH knockout mouse." American Journal of Physiology Endocrinology and Metabolism. 2006;291(6):E1290-E1294.
- Raun K, Hansen BS, Johansen NL, et al. "Ipamorelin, the first selective growth hormone secretagogue." European Journal of Endocrinology. 1998;139(5):552-561.
- WADA. "World Anti-Doping Agency Prohibited List 2025." World Anti-Doping Agency. 2025. wada-ama.org.
- Gadde KM, Allison DB, Ryan DH, et al. "Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial." Lancet. 2011;377(9774):1341-1352.
- Drucker DJ. "Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1." Cell Metabolism. 2018;27(4):740-756.
- Freda PU. "Current concepts in the biochemical assessment of the patient with acromegaly." Growth Hormone and IGF Research. 2003;13(4):171-184. (GH receptor physiology context)
Footer Disclaimers
Platform: FormBlends is an informational platform. Content on this page is for educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.
Research Compound or Compounded Medication: Several peptides discussed on this page (including CJC-1295, Ipamorelin, AOD-9604, GHRP-2, and GHRP-6) are not FDA-approved drugs. They are sold as research chemicals for laboratory use only and are not approved for human administration. Discussion of these compounds is for scientific education, not to encourage or facilitate their use in humans.
Results: Clinical outcomes cited are population-level trial results. Individual responses vary substantially. Weight loss outcomes described from clinical trials may not reflect results achievable outside of controlled trial conditions with dietary and behavioral co-interventions.
Trademark: Wegovy, Ozempic, Zepbound, Mounjaro, Saxenda, and Victoza are registered trademarks of their respective owners. FormBlends has no affiliation with Novo Nordisk, Eli Lilly, or any pharmaceutical manufacturer referenced on this page.